In this issue of Clinical Cancer Research, Kong and colleagues (1) show use of a second-generation chimeric antigen receptor (CAR) modified to retarget autologous T cells to the interleukin-13 receptor a2 (IL13Ra2), preferentially expressed on glioma tumors.
Malignant primary brain tumors account for more deaths than cancer of the kidney or melanoma, and now represent the most common cause of cancer-related death in children and young adults. Current therapy for glioblastoma, the most common and malignant of these tumors, consists of surgical resection followed by radiation and chemotherapy, which is limited by toxicity to systemic tissues and surrounding eloquent brain. Despite aggressive therapy, these tumors remain universally fatal; therefore it is important to develop alternate therapies for this deadly disease.
In contrast with current nonspecific therapies, immunotherapy, which has recently been shown to be effective in several phase III clinical trials for patients with metastatic melanoma and prostate cancer, offers a specific targeted approach for the eradication of tumors (2, 3) . Natural selection and evolution have provided us with an immune system capable of responding to cancerous cells and destroying them so long as they can be identified as "dangerous." However, an ongoing evolutionary arms race driven by mutations in rapidly dividing cancerous cells has also resulted in tumors with the ability to "hide" from the immune system by suppression of the MHC and various antigen-presentation mechanisms associated with this pathway and to attenuate the immune response against them. In addition, many tumor-associated antigens are overexpressed "self" antigens, shared between tumors and normal tissues. Because of the basic immunologic process of thymic selection, most T cells equipped with receptors that would otherwise recognize and destroy these antigens have already been eliminated to prevent autotoxicity. Thus, the remaining pool of potentially tumor-reactive T cells tend to be fairly infrequent in number and of low avidity and reactivity for the selected antigen, so mount a poor endogenous antitumor immune response.
One particular type of immunotherapy can overcome each of these problems. It involves adoptive transfer of genetically redirected T cells and stands out as a promising treatment able to eliminate brain tumor deposits in patients with metastatic cancer (4, 5) . CARs combine ex vivo engineered antigen recognition regions with T-cell signaling molecules that induce T-cell activation upon encounter of target antigen (6) . Expressing CARs in T cells results in T-cell activation very similar to that observed by triggering the endogenous T-cell receptor (TCR). However, unlike TCR, CAR receptors are not MHC restricted, and therefore, the same CAR receptor can be used for any patient regardless of haplotype and can additionally circumvent tumor-mediated T-cell escape mechanisms, such as the loss of MHC molecules. In addition, CARs can be further engineered, adding costimulatory and antiapoptotic molecules, such as CD28 and 4-1BB, resulting in second-and third-generation constructs, respectively, conferring improved activity and survival to T cells.
Early clinical trials with CARs have generally used firstgeneration vector designs whereby T cells did not persist (7), or showed high potency against shared self-tissue antigens (HER2/ERBB2) resulting in severe toxicity (8) . However, recent clinical trials using improved second-and thirdgeneration CAR vectors targeting CD19 to treat patients with disseminated lymphoma have shown these agents to be safe and produced dramatic clinical responses in patients with advanced disease (9-11). As CARs are remarkably powerful, shown by the elimination of all target antigenexpressing cells, including those in nonmalignant tissues in patients receiving CAR-transduced cells (9), the target antigen must be carefully selected to reduce the risk of lifethreatening autoimmunity.
Although tissues outside the central nervous system (CNS) may undergo collateral damage without causing death, in the brain this toxicity would likely be fatal. To avoid CNS toxicity while targeting brain tumors, selected antigenic targets must be present only on tumors, and these must be recognized with exquisite specificity by the immune system. Brain tumors, are known to express tumor-specific antigens, including IL13Ra2; in comparison, normal tissues tend to express IL13Ra1.
In this issue, Kong and colleagues (1) have built upon previous works (12) using "zetakine" CARs to target IL13Ra2. Here, the authors have generated a second-generation IL13 "zetakine" CAR, incorporating CD28 costimulation, with dual IL13 mutations specifically designed to decrease binding to IL13Ra1, while increasing avidity for IL13Ra2 ( Fig. 1; ref. 1 ). They show specificity and function against IL13Ra2-expressing gliomas in vitro, resulting in type I immune cytokine production, T-cell proliferation, and target cell lysis. In vivo, using direct intratumoral CAR Tcell injection, this translates into increased T-cell infiltration of tumor, and treatment of 6-day established intracranial glioma in a nude rat xenograft model, shown by brain scan imaging, immunohistochemistry, and increased animal survival.
Many potentially active therapeutic agents for brain tumors are ineffective by systemic administration because they are unable to cross the blood-brain barrier (BBB). As intracerebral administration bypasses the BBB, it increases the amount of treatment that can be successfully delivered into the brain, while minimizing the potential for systemic toxicity and improving treatment effect. In their experiments, Kong and colleagues deliver CAR T cells directly to the tumor bed in vivo. This is clinically relevant, as intracavitary bolus injection and convection-enhanced delivery are regularly used clinically to deliver therapeutic agents directly intratumorally to patients with brain tumors.
Although such potent therapeutic intervention should be undertaken with caution, this type of gene-engineered tumor immunotherapy has the potential to be translated into meaningful treatment of patients with brain tumors.
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